Literature DB >> 29442155

Outcomes and prognostic factors of selective lateral pelvic lymph node dissection with preoperative chemoradiotherapy for locally advanced rectal cancer.

Takeru Matsuda1, Yasuo Sumi2, Kimihiro Yamashita3, Hiroshi Hasegawa3, Masashi Yamamoto3, Yoshiko Matsuda3, Shingo Kanaji3, Taro Oshikiri3, Tetsu Nakamura3, Satoshi Suzuki3, Yoshihiro Kakeji3.   

Abstract

PURPOSE: The clinical significance of preoperative chemoradiotherapy (CRT) and lateral lymph node dissection (LLND) for locally advanced rectal cancer remains unclear. We have employed total mesorectal excision and selective LLND following preoperative CRT for patients with locally advanced rectal cancer. The validity of our strategy was evaluated.
METHODS: A total of 45 patients with locally advanced rectal cancer who underwent curative surgery after CRT from November 2005 to September 2016 were retrospectively analyzed. LLND was performed only for the patients with lateral lymph nodes suspected to have metastasis based on the pretreatment images.
RESULTS: Rates of 5-year overall survival (OS) and 5-year relapse-free survival (RFS) were 85.7 and 61.8%, respectively. Univariate and multivariate analyses detected only histological response (grades 2 and 3 vs. grade 1) as a significant prognostic factor for OS and local recurrence. ypN and ypStage were significant factors for RFS by univariate analysis, while no significant factor was detected by multivariate analysis. There was no significant factor for distant recurrence. In good responders (grades 2 and 3), the local recurrence rate was 0% (P = 0.006, vs. grade 1), while distant recurrence developed in 4 of 20 cases (20%, P = 0.615, vs. grade 1). There was no local recurrence in LLND (-) group regardless the histological response.
CONCLUSIONS: Although selective LLND with preoperative CRT seems effective and valid for good responders, new treatment strategy is necessary for poor responders. Therefore, development of reliable biomarkers for histological response to CRT is an urgent need.

Entities:  

Keywords:  CRT; Chemoradiotherapy; Lateral lymph node dissection; Rectal cancer

Mesh:

Year:  2018        PMID: 29442155     DOI: 10.1007/s00384-018-2974-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  30 in total

1.  Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.

Authors:  Shin Fujita; Takayuki Akasu; Junki Mizusawa; Norio Saito; Yusuke Kinugasa; Yukihide Kanemitsu; Masayuki Ohue; Shoichi Fujii; Manabu Shiozawa; Takashi Yamaguchi; Yoshihiro Moriya
Journal:  Lancet Oncol       Date:  2012-05-15       Impact factor: 41.316

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Seung-Yong Jeong; Dong Hyun Choi; Dae Yong Kim; Kyung Hae Jung; Sung Ho Moon; Hee Jin Chang; Seok-Byung Lim; Hyo Seong Choi; Jae-Gahb Park
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

4.  Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.

Authors:  Atsushi Ogura; Takashi Akiyoshi; Toshiya Nagasaki; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Yosuke Fukunaga; Masashi Ueno; Hiroya Kuroyanagi
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

5.  Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

Authors:  J V Schou; F O Larsen; L Rasch; D Linnemann; J Langhoff; E Høgdall; D L Nielsen; K Vistisen; A Fromm; B V Jensen
Journal:  Ann Oncol       Date:  2012-04-02       Impact factor: 32.976

6.  Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer.

Authors:  M Ueno; M Oya; K Azekura; T Yamaguchi; T Muto
Journal:  Br J Surg       Date:  2005-06       Impact factor: 6.939

7.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

8.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

9.  Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.

Authors:  Takashi Akiyoshi; Masashi Ueno; Kiyoshi Matsueda; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Yosuke Fukunaga; Toshiyuki Unno; Atsuhiro Kano; Hiroya Kuroyanagi; Masatoshi Oya; Toshiharu Yamaguchi; Toshiaki Watanabe; Tetsuichiro Muto
Journal:  Ann Surg Oncol       Date:  2013-08-21       Impact factor: 5.344

10.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

View more
  17 in total

1.  Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Geerard L Beets; Harm J T Rutten; Miranda Kusters
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

Review 2.  Lateral Pelvic Lymph Node Metastases in Rectal Cancer: A Systematic Review.

Authors:  Y Atef; T W Koedam; S E van Oostendorp; H J Bonjer; A R Wijsmuller; J B Tuynman
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

Review 3.  Total mesorectal excision with and without lateral lymph node dissection: a systematic review of the literature.

Authors:  Gregoire Longchamp; Jeremy Meyer; Niki Christou; Sotirios Popeskou; Elin Roos; Christian Toso; Nicolas C Buchs; Frédéric Ris
Journal:  Int J Colorectal Dis       Date:  2020-05-27       Impact factor: 2.571

4.  Predicting lateral pelvic lymph node metastasis based on magnetic resonance imaging before and after neoadjuvant chemotherapy for patients with locally advanced lower rectal cancer.

Authors:  Yuki Sekido; Junichi Nishimura; Shiki Fujino; Takayuki Ogino; Norikatsu Miyoshi; Hidekazu Takahashi; Mamoru Uemura; Naotsugu Haraguchi; Taishi Hata; Chu Matsuda; Tsunekazu Mizushima; Kohei Murata; Junichi Hasegawa; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2019-10-08       Impact factor: 2.549

5.  Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Geerard L Beets; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Harm J T Rutten; Jurriaan B Tuynman; Miranda Kusters
Journal:  JAMA Surg       Date:  2019-09-18       Impact factor: 14.766

6.  Laparoscopic versus open lateral pelvic lymph node dissection in locally advanced rectal cancer: multicentre retrospective cohort study.

Authors:  Han-Ki Lim; Minjung Kim; Ji Won Park; Seung-Bum Ryoo; Kyu Joo Park; Heung-Kwon Oh; Duck-Woo Kim; Sung-Bum Kang; Dong Woon Lee; Sung Chan Park; Jae Hwan Oh; Seung-Yong Jeong
Journal:  BJS Open       Date:  2022-05-02

7.  Laparoscopic lateral pelvic lymph node dissection for lower rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Takeru Matsuda; Hiroshi Hasegawa; Kimihiro Yamashita; Tomoko Tanaka; Masashi Yamamoto; Shingo Kanaji; Taro Oshikiri; Tetsu Nakamura; Yasuo Sumi; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Surg Endosc       Date:  2019-10-18       Impact factor: 4.584

8.  MRI-detected extramural vascular invasion potentiates the risk for pathological metastasis to the lateral lymph nodes in rectal cancer.

Authors:  Atsushi Hamabe; Masayuki Ishii; Koichi Onodera; Kenji Okita; Toshihiko Nishidate; Koichi Okuya; Emi Akizuki; Ryo Miura; Takahiro Korai; Masamitsu Hatakenaka; Ichiro Takemasa
Journal:  Surg Today       Date:  2021-03-04       Impact factor: 2.549

9.  What is the role of lateral lymph node dissection in rectal cancer patients with clinically suspected lateral lymph node metastasis after preoperative chemoradiotherapy? A meta-analysis and systematic review.

Authors:  Xuyang Yang; Shuo Yang; Tao Hu; Chaoyang Gu; Mingtian Wei; Xiangbing Deng; Ziqiang Wang; Zongguang Zhou
Journal:  Cancer Med       Date:  2020-04-30       Impact factor: 4.452

Review 10.  Lateral pelvic lymph node dissection and radiation treatment for rectal cancer: Mutually exclusive or mutually beneficial?

Authors:  Tarik Sammour; George J Chang
Journal:  Ann Gastroenterol Surg       Date:  2018-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.